FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281633027> ?p ?o ?g. }

• W4281633027 endingPage "235" @default.
• W4281633027 startingPage "229" @default.
• W4281633027 abstract "Ocular myasthenia gravis (MG) is the most common phenotype of MG at onset. A variable percentage of these patients develop secondary generalisation; the risk factors for conversion and the protective effect of immunosuppressive treatment are currently controversial. We designed a retrospective single-centre study with the aim of describing the demographic, clinical, and laboratory characteristics of a Spanish cohort of patients with ocular MG from Hospital Universitario de Albacete from January 2008 to February 2020. We selected 62 patients with ocular MG from a cohort of 91 patients with MG (68.1%). Median age at diagnosis was 68 (IQR, 52–75.3), and men accounted for 61.3% of the sample (n = 38). Most patients presented very late-onset ocular MG (n = 34, 54.8%). Binocular diplopia was the most frequent initial symptom (51.7%). The rate of progression to generalised MG was 50% (n = 31), with a median time of 6 months (IQR, 2–12.8). Female sex (OR: 5.46; 95% CI, 1.16-25-74; P= .03) and anti—acetylcholine receptor antibodies (OR: 8.86; 95% CI, 1.15–68.41; P = .04) were significantly associated with the risk of developing generalised MG. The conversion rate observed in our series is relatively high. Generalisation of MG mainly occurs during the first 2 years of progression, and is strongly associated with female sex and especially with the presence of anti—acetylcholine receptor antibodies. La miastenia gravis ocular (MGo) es la forma de presentación de la enfermedad más frecuente. Un porcentaje variable de estos pacientes desarrollan una forma generalizada (MGg), siendo los factores de riesgo de conversión y el efecto protector del tratamiento inmunosupresor objeto de controversia en el momento actual. Diseñamos un estudio monocéntrico retrospectivo, con el objetivo de describir las características demográficas, clínicas y de laboratorio de una cohorte española de MGo, a partir de una serie de MG registrada en el Hospital Universitario de Albacete desde enero del 2008 hasta febrero de 2020. Seleccionamos 62 pacientes con MGo de una cohorte de 91 sujetos con MG (68,1%). La mediana de edad al diagnóstico fue de 68 (RIQ 52–75,3), con predominio de MGo de inicio muy tardío (n = 34, 54,8%) y de varones (n = 38, 61,3%). La diplopía binocular fue el síntoma inicial más frecuente (51,7%). La tasa de conversión a MGg fue del 50% (n = 31), con una mediana de tiempo de seis meses (RIQ 2–12,8). Encontramos asociación significativa entre ser mujer (OR: 5,46, IC 95% 1,16-25-74, p = 0,03) y tener AcAchR (OR: 8,86, IC 95% 1,15-68,41, p = 0,04), con el riesgo de desarrollar una MGg. La tasa de conversión de MGo en nuestra serie es relativamente elevada. La generalización tiene lugar principalmente durante los primeros dos años de evolución y está asociada al sexo femenino y, sobre todo, a la presencia de AcAchR." @default.
• W4281633027 created "2022-06-13" @default.
• W4281633027 creator A5002659783 @default.
• W4281633027 creator A5010786406 @default.
• W4281633027 creator A5013392819 @default.
• W4281633027 creator A5019888564 @default.
• W4281633027 creator A5038151978 @default.
• W4281633027 creator A5039959313 @default.
• W4281633027 creator A5059042129 @default.
• W4281633027 date "2023-05-01" @default.
• W4281633027 modified "2023-10-01" @default.
• W4281633027 title "Ocular myasthenia gravis and risk factors for developing a secondary generalisation: description of a Spanish series" @default.
• W4281633027 cites W1661216026 @default.
• W4281633027 cites W2015385567 @default.
• W4281633027 cites W2028108956 @default.
• W4281633027 cites W2035289940 @default.
• W4281633027 cites W2041684666 @default.
• W4281633027 cites W2053680723 @default.
• W4281633027 cites W2069768552 @default.
• W4281633027 cites W2072475795 @default.
• W4281633027 cites W2078966021 @default.
• W4281633027 cites W2089117937 @default.
• W4281633027 cites W2119417201 @default.
• W4281633027 cites W2158122370 @default.
• W4281633027 cites W2285766749 @default.
• W4281633027 cites W2312452396 @default.
• W4281633027 cites W2461303519 @default.
• W4281633027 cites W2607192280 @default.
• W4281633027 cites W2659815784 @default.
• W4281633027 cites W2735026826 @default.
• W4281633027 cites W2755762791 @default.
• W4281633027 cites W2761621565 @default.
• W4281633027 cites W2787901111 @default.
• W4281633027 cites W2793756090 @default.
• W4281633027 cites W2806187231 @default.
• W4281633027 cites W2891865821 @default.
• W4281633027 cites W2913761737 @default.
• W4281633027 cites W2975901834 @default.
• W4281633027 cites W2990454636 @default.
• W4281633027 cites W3008214101 @default.
• W4281633027 cites W992550965 @default.
• W4281633027 doi "https://doi.org/10.1016/j.nrleng.2020.09.004" @default.
• W4281633027 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35637136" @default.
• W4281633027 hasPublicationYear "2023" @default.
• W4281633027 type Work @default.
• W4281633027 citedByCount "0" @default.
• W4281633027 crossrefType "journal-article" @default.
• W4281633027 hasAuthorship W4281633027A5002659783 @default.
• W4281633027 hasAuthorship W4281633027A5010786406 @default.
• W4281633027 hasAuthorship W4281633027A5013392819 @default.
• W4281633027 hasAuthorship W4281633027A5019888564 @default.
• W4281633027 hasAuthorship W4281633027A5038151978 @default.
• W4281633027 hasAuthorship W4281633027A5039959313 @default.
• W4281633027 hasAuthorship W4281633027A5059042129 @default.
• W4281633027 hasBestOaLocation W42816330271 @default.
• W4281633027 hasConcept C126322002 @default.
• W4281633027 hasConcept C141071460 @default.
• W4281633027 hasConcept C167135981 @default.
• W4281633027 hasConcept C187212893 @default.
• W4281633027 hasConcept C2777960172 @default.
• W4281633027 hasConcept C2778105408 @default.
• W4281633027 hasConcept C2779615886 @default.
• W4281633027 hasConcept C2780581723 @default.
• W4281633027 hasConcept C71924100 @default.
• W4281633027 hasConcept C72563966 @default.
• W4281633027 hasConcept C90924648 @default.
• W4281633027 hasConceptScore W4281633027C126322002 @default.
• W4281633027 hasConceptScore W4281633027C141071460 @default.
• W4281633027 hasConceptScore W4281633027C167135981 @default.
• W4281633027 hasConceptScore W4281633027C187212893 @default.
• W4281633027 hasConceptScore W4281633027C2777960172 @default.
• W4281633027 hasConceptScore W4281633027C2778105408 @default.
• W4281633027 hasConceptScore W4281633027C2779615886 @default.
• W4281633027 hasConceptScore W4281633027C2780581723 @default.
• W4281633027 hasConceptScore W4281633027C71924100 @default.
• W4281633027 hasConceptScore W4281633027C72563966 @default.
• W4281633027 hasConceptScore W4281633027C90924648 @default.
• W4281633027 hasIssue "4" @default.
• W4281633027 hasLocation W42816330271 @default.
• W4281633027 hasLocation W42816330272 @default.
• W4281633027 hasOpenAccess W4281633027 @default.
• W4281633027 hasPrimaryLocation W42816330271 @default.
• W4281633027 hasRelatedWork W2012045204 @default.
• W4281633027 hasRelatedWork W2069468042 @default.
• W4281633027 hasRelatedWork W2281857454 @default.
• W4281633027 hasRelatedWork W2380162649 @default.
• W4281633027 hasRelatedWork W2395295677 @default.
• W4281633027 hasRelatedWork W2492545249 @default.
• W4281633027 hasRelatedWork W2607192280 @default.
• W4281633027 hasRelatedWork W2971622769 @default.
• W4281633027 hasRelatedWork W2980301535 @default.
• W4281633027 hasRelatedWork W4232881060 @default.
• W4281633027 hasVolume "38" @default.
• W4281633027 isParatext "false" @default.
• W4281633027 isRetracted "false" @default.
• W4281633027 workType "article" @default.